Wyeth Effexor Promotions Cited For Superiority Claims In FDA Letter

The ad division letter follows an Office of Personnel Management Inspector General investigation into Wyeth's Effexor marketing practices. FDA asserts that Wyeth's claims of superiority to SSRIs are unsubstantiated.